药物审查在应对社区老年患者药物相关问题中的现状

The status of medication review in addressing drug-related problems of elderly patients in the community

随着我国人口老龄化日益加剧,社区老年患者药物相关问题的发生率也逐渐增加。药物相关问题会导致社区老年患者跌倒、衰弱等不良健康结局的发生率增加。药物审查是应对药物相关问题的有效手段之一。欧美国家应对药物相关问题的药物审查模式已发展数十年,其中,英国的药物审查模式更注重社区养老机构老年患者的药物治疗管理,而美国与澳大利亚的药物审查模式的覆盖范围更为广泛(包含所有社区老年患者),药物审查频率也更为明确和规范。与上述国家相比,我国的药物审查模式建设起步较晚。我国可借鉴英、美、澳等国的先进经验,积极探索构建适宜我国国情的药物审查模式,以提高社区老年患者健康水平、节约社会公共医疗资源。

With the increasing aging of our population,the incidence of drug-related problems among elderly patients in the community is gradually increasing.Drug-related problems can lead to an increased incidence of adverse health outcomes such as falls and frailty in elderly patients in the community.Medication review is one of the effective means of addressing drug-related problems.The medication review models in Europe and the United States have been developed for decades to address drug-related problems;medication review model in the United Kingdom focuses on the management of drug therapy for elderly patients in aged care facilities,while the medication review models in the United States and Australia have a broader scope(covering all elderly patients in the community),and the frequency of medication reviews in the United States and Australia are clearer and more standardized.Compared with the above countries,China’s medication review model has a late start.Our country can learn from the advanced experience of the United Kingdom,the United States,Australia and other countries,actively explore and build a drug review model suitable for China’s national conditions,so as to improve the health level of elderly patients in the community and save social public medical resources.